72263 | Outcomes of Patients Deemed Unsuitable for Transcatheter Tricuspid Valve Replacement

Document Type

Conference Proceeding

Publication Date

6-1-2025

Publication Title

Struct Heart

Abstract

Background: Transcatheter Tricuspid Valve Replacement (TTVR) has shown promise for patients with severe Tricuspid Regurgitation (TR). Some patients may not be eligible due to anatomic limitations. We sought to describe the outcomes of patients referred for Transcatheter Tricuspid Valve Intervention (TTVI), who were deemed ineligible for TTVR. Methods: This was a single-center, retrospective study of eligible individuals referred for TTVI from February 2024 to February 2025. Patients were evaluated by a multi-disciplinary team that assessed eligibility for TTVI, with a primary goal of valve replacement if anatomically feasible. Data on demographics, clinical characteristics and outcomes were collected from medical records. Results: Out of 185 patients evaluated for TTVR, 24 (12.97%) were deemed unsuitable (Figure 1). Ten (41.67%) underwent T-TEER, and 14 (58.33%) received medical therapy. In the T-TEER group, 37.5% had a reduction in TR severity at one-month follow-up, though not statistically significant (p=0.11). KCCQ scores showed a trend toward improvement (p=0.10). No significant differences were found in rehospitalization (p=0.80) or mortality rates (p>0.50) between groups. [Formula presented] Conclusion: In this initial commercial experience, rates of ineligibility for TTVR were lower than previously described. For those patients who did undergo T-TEER, rates of TR reduction and KCCQ improvement were similar to medical therapy. Additional percutaneous solutions are needed to address these patients.

Volume

9

Find It @ Sladen

Share

COinS